Every­one wants in on GLP-1: Pfiz­er dos­es first pa­tient in PhII tri­al for di­a­betes and obe­si­ty drug, pays So­sei $10M

So­sei Hep­tares an­nounced Wednes­day morn­ing that Pfiz­er dosed its first pa­tient in a Phase II tri­al as part of their part­ner­ship on a GLP-1 ag­o­nist known as PF-07081532.

So­sei will get $10 mil­lion as a re­sult of the drug pro­gress­ing in­to a Phase II tri­al. The drug was dis­cov­ered by Pfiz­er sci­en­tists but used So­sei’s dis­cov­ery plat­form.

The Phase II tri­al will aim to test Pfiz­er’s drug in 780 par­tic­i­pants with ei­ther Type 2 di­a­betes or obe­si­ty. For the Type 2 di­a­betes por­tion of the tri­al, aside from Pfiz­er’s drug and place­bo, some pa­tients will al­so be ran­dom­ized to No­vo Nordisk’s Ry­bel­sus, a GLP-1 pill ap­proved for Type 2 di­a­betes in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER